YTHDF1 and hepatocellular carcinoma: This study suggests that the m6A-YTHDF1-EGFR axis promotes HCC progression following IRFA, and that targeted combined inhibition of m6A modification and EGFR represents a potential strategy for preventing HCC recurrence after RFA treatment.